Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin for Early Fetal Growth Restriction
NCT04762992Phase 3Enrolling by invitation
- Sponsor
- Centro Hospitalar Universitário de Lisboa Central
- Start
- Jul 2022
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of enoxaparin in fetal growth restriction (FGR), sponsored by Centro Hospitalar Universitário de Lisboa Central. Started Jul 2022; status: enrolling by invitation.
02
Drugs
enoxaparin
03
Conditions
fetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT04762992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762992.